A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Conditions

• Chronic Weight Management
• Obesity
• Overweight
• Type2 Diabetes Mellitus

Eligibility Criteria

Sex

ALL

Age

18 Years - 79 Years

Healthy Volunteers

Accepted

Interventions

• aleniglipron — DRUG
  Drug: aleniglipron administered orally
• aleniglipron — DRUG
  Drug: aleniglipron administered orally
• aleniglipron — DRUG
  Drug: aleniglipron administered orally
• Placebo — DRUG
  Drug: placebo administered orally

Study Details

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.

Key Dates

First listed

Jun 17, 2026

Start date

Jul 17, 2026

Status verified

Jun 2026

Primary completion

Sep 30, 2028

Completion

Nov 30, 2028

Study Design

Enrollment

1,100 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: aleniglipron Arm 1
  Participants will receive aleniglipron administered orally.
• Experimental: aleniglipron Arm 2
  Participants will receive aleniglipron administered orally.
• Experimental: aleniglipron Arm 3
  Participants will receive aleniglipron administered orally.
• Placebo Comparator: Placebo Arm 4
  Participants will receive placebo administered orally.

Primary Outcome Measure

Percent change in body weight from Baseline [ Time Frame: Baseline and week 76 ]

Central Contacts

• Medical Director
  1-650-457-1959
  [email protected]

Locations (74)

Find similar trials in Birmingham, AL

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
• New Heart Imaging Techniques to Evaluate Possible Heart Disease
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland